Observational studyActa oncologica (Stockholm, Sweden)2025
Impact of the COVID-19 pandemic on the quality of life of early breast cancer patients undergoing adjuvant chemotherapy - an observational, multicenter study.
Observational study in Acta oncologica (Stockholm, Sweden), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeWe evaluated the impact of the coronavirus disease 2019 (COVID-19) pandemic on health-related quality of life (HRQoL) in early-stage breast cancer patients receiving adjuvant chemotherapy. PATIENTS AND
methodsThe study involved 180 patients with stage I-III breast cancer who initiated adjuvant chemotherapy between June 2020 and May 2021. The pre-pandemic comparison data included 113 early breast cancer patients who began adjuvant chemotherapy between November 2018 and August 2019. HRQoL was assessed using the EORTC QLQ-C30 at baseline and again after 3 and 6 months. The subscales were compared between the COVID-19 pandemic and the pre-pandemic eras.
resultsWe observed deterioration on almost all HRQoL subscales of the patients treated during the pandemic from baseline to 3 months. After the chemotherapy at 6 months, the scales remained deteriorated, whereas only appetite loss and emotional functioning improved. A comparison between the pandemic and the pre-pandemic eras revealed that several HRQoL subscales showed better results during chemotherapy in the pandemic era. Global health and role functioning at 6 months presented declined levels during the pandemic.
interpretationThe well-being of breast cancer patients during the chemotherapy treatment in the pandemic era was moderately better than in the pre-pandemic era. Patients in the pandemic era might have reported fewer symptoms during the treatment, as the focus was on the COVID-19 pandemic and its restrictions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.